Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment Relapsed/Refractory Multiple Myeloma Patients
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Pharmacodynamics
- 02 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.
- 02 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.
- 15 Sep 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.